Search clinical trials for: Immune Checkpoint Inhibitors

Total 108262 results

Bolt Biotherapeutics, Inc.

Recruiting

Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Clear Cell Renal Cell Carcinoma | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer

United States
Dan Zandberg

Recruiting

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
Neonc Technologies, Inc.

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions

United States
Christine Ryan
Genentech, Inc.

Recruiting

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Chronic Lymphocytic Leukemia | Richter's Transformation

United States
University of Cologne

Not yet recruiting

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma (Pembro-FLASH)

Hodgkin Lymphoma

Germany
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Gulam Manji
Arcus Biosciences, Inc.

Recruiting

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc)

Pancreatic Ductal Adenocarcinoma

United States
Nataliya Uboha
Gilead Sciences; University of Wisconsin, Madison; Arcus Biosciences, Inc.

Recruiting

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Carcinoma

United States
Ari Raphael
Merck Sharp & Dohme LLC; Bar-Ilan University, Israel

Not yet recruiting

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Non-small Cell Lung Cancer Metastatic
Jiangsu Cancer Institute & Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM (HaRyPOT)

Colorectal Liver Metastases

China
National Cancer Institute (NCI)

Not yet recruiting

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Testicular Germ Cell Tumors

United States
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
First Affiliated Hospital of Guangxi Medical University

Recruiting

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Hepatocellular Carcinoma Non-resectable | Immune Checkpoint Inhibitors | Portal Vein Tumor Thrombus

China
Shanghai Minimally Invasive Surgery Center

Recruiting

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Gastric Cancer Stage IIIB-IIIC

China
Tom Appleton
Western University; Canadian Research Group in Immuno-Oncology

Not yet recruiting

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Inflammatory Arthritis | Immune-related Adverse Event
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Taiwan, Italy, Australia, Malaysia, United States, Netherlands, Turkey, France, Germany
Molecular Templates, Inc.

Recruiting

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Cullinan Therapeutics Inc.

Recruiting

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid Tumors

Australia, United States, Canada
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Isala

Recruiting

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie (MINUTE)

Oncology | Infusion Reaction

Netherlands
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Diwakar Davar
Merck Sharp & Dohme LLC; Gateway for Cancer Research

Not yet recruiting

Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

PD-1 Refractory Advanced Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC; G1 Therapeutics, Inc.

Recruiting

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)

Metastatic Triple-Negative Breast Cancer

United States
Zhongda Hospital

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
Evopoint Biosciences Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Carcinoma | Cervical Cancer | Prostate Cancer | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Other Solid Tumors

China
Institut Mutualiste Montsouris
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside (VICKI)

Renal Cell Carcinoma | Cancer | Bladder Cancer | MSI-H Cancer

France
German Society for Pediatric Oncology and Hematology...
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms

Germany
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Georgetown University
Bristol-Myers Squibb; Targovax ASA; Janssen, LP

Recruiting

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX)

Pancreatic Ductal Adenocarcinoma | Refractory Non-Small Cell Lung Cancer

United States
The Netherlands Cancer Institute

Not yet recruiting

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (CoLBAt)

Metastatic Microsatellite-stable Colorectal Cancer
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
Alliance for Clinical Trials in Oncology

Not yet recruiting

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
University of Alabama at Birmingham

Recruiting

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) (MRD GATE RCC)

Renal Cell Carcinoma

United States
Institut Mutualiste Montsouris
Institut Curie

Recruiting

Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors (TILT)

Cancer | Immune Checkpoint Inhibitor | Cardiovascular Biomarkers

France
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Tang-Du Hospital

Recruiting

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Chemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | Neoadjuvent

China
Omico
Hoffmann-La Roche; The George Institute for Global Health, Australia

Recruiting

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)

Solid Tumor, Adult

Australia
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Cancer Prevention Research Institute of Texas

Recruiting

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Oligometastatic Renal Cell Carcinoma

United States
Ralph G Zinner
Bristol-Myers Squibb

Recruiting

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Lung Cancer, Nonsmall Cell | Lung Cancer Stage III

United States
Lithuanian University of Health Sciences
Research Council of Lithuania

Recruiting

The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer (LUCACRIMUNO)

Lung Cancer Stage IV

Lithuania
University of Texas Southwestern Medical Center
Genentech, Inc.

Recruiting

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Colorectal Cancer

United States
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States

Search clinical trials for: Immune Checkpoint Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations